



SciGen and Ferring International Terminate Relationship

15th August 2007: SciGen Limited (ASX:SIE) announces that it has ceased its distribution of Ferring International Human Growth Hormone. This decision has come after a long and protracted dispute that began when Ferring acquired Biotechnology General (IL) Ltd. In 2005.

SciGen and Ferring agreed to terminate their distribution agreement for most of the Asia Pacific region, effective immediately.

SciGen will soon be introducing a new human Growth Hormone to the Asia Pacific region that is presently approved by most health regulatory agencies such as the FDA in the USA, EMEA in the EEC, Japan and other major markets. "SciGen looks forward to reenter the market as soon as possible, continue its commitment to this franchise and start its promotional activities in support of the new product which offers a broader list of approved indications and greater ease of administration to the patients" stated SciGen Chairman & CEO Mr. Saul Mashaal.

In spite of this transition to a novel human Growth Hormone, SciGen has maintained sales and profit targets for FY 2006. SciGen expects to meet revenue projections for this fiscal year ending in December 2007.

About Human Growth Hormone:

Human Growth hormone (HGH) or somatotropin is a protein hormone which stimulates growth and cell reproduction in humans. It is a 191-amino acid, single chain polypeptide hormone which is synthesized, stored, and secreted by the somatotroph cells within the lateral wings of the anterior pituitary gland. SciTropin™ is recombinant human growth hormone synthesised in *E. coli* cells. It is identical to naturally-occurring human growth hormone. The new formulated SciTropin™ is used for the treatment of short stature due to growth hormone deficiency in children, the chromosomal abnormality Turner syndrome in which females lack one of the two X chromosomes, chronic kidney problems, muscle wasting in AIDS and other conditions and growth hormone deficiency in adults.

About SciGen:

SciGen Ltd is a biopharmaceutical company involved in commercializing later stage research. It co-develops and markets biopharmaceutical products for human healthcare. SciGen focuses in the areas of gastroenterology, endocrinology and immunology. Its product portfolio includes vaccines and therapeutics.

SciGen acquires rights to manufacture, distribute and market biopharmaceutical products under exclusive licensing arrangements. SciGen's portfolio currently includes proprietary biotechnology-derived products, and Biosimilar products, which allow for



faster entry into the market, as Biosimilar products have undergone much of the clinical development and trials required to bring drugs to market. This minimizes the risks

associated with early stage product development. SciGen currently undertakes R&D activities in collaboration with strategic partners and institutions.

SciGen's competitive advantage is in identifying research with commercial potential at an early stage to which it adds its expertise in clinical development, gaining regulatory approval and bringing products to market.

SciGen is a Singaporean biotechnology company, established in 1988 and listed on the Australian Stock Exchange (ASX code SIE). SciGen is headquartered in Singapore, with subsidiary companies in the USA, Australia, S. Korea, Hong Kong, Philippines, Vietnam, Israel and India, a Joint Venture in China, commercial partners in Europe and collaborative partners in the USA and the Netherlands

Further information:

Company – Investor Relations	Company
Ms. Maria Aroyan SciGen Australia +61 2 9485 1800 email: mariaaroyan@scigen.com.au	Saul Mashaal Chairman, Founder & CEO SciGen Ltd. + 61 2 9485 1800 +65 9630 5691 (Mobile)